Friday, February 02, 2024 1:14:07 PM
There were some big block trades going on indicating some potential accumulation back then but then there was a change in wording from 1 million pages to 1.7 million pages if you recall. That obviously ended up creating a change in timeline and also a likely change in accumulation strategy which led to last summer’s price melt down. This makes complete sense if there was a side by side submission strategy going on and Edens finally was ready or nearly ready to be placed into the submission as well as the proteomics data that strengthens the case for tissue agnostic designation that we were made aware of. The juggling and perhaps expected potential breakthrough with Edens would have been happening all during this time. I was expecting an announcement about Edens after almost a year without any definitive news back then and expected that would heat up speculation about a partnership or CRL announcement. I think those that were anccumulating were thinking along the same lines. I also think some big investors got anxious enough to sign an NDA during this time and li and behold, none of them are saying much of anything anymore.
Anything that gives Wall Street and investors reason to believe that revenue is on the way from expected approval would provide a big boost. Partnerships tend to solidify that expectation. That never happened timely last year and now it seems no one is going to say anything before approval even if payments for milestones get reported in a 10Q. Perhaps Merck or someone else NWBO is dealing with wants it this way for strategic reasons. I think we all understand why that may be even if we need to be put through the manipulation grinder until news because of this. Lots of moving parts that everyone seems to be very quiet about, not just NWBO. If this is all happening and a few big vocal supporters signed NDAs just to prevent a sell off by them then it goes a long way to explain the current lack of price support. Best wishes.
Recent NWBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM